Dr. Maurizio Cereda, MD

Claim this profile
Studies Acute Respiratory Distress Syndrome
Studies Neonatal Respiratory Distress Syndrome
1 reported clinical trial
1 drug studied

Clinical Trials Maurizio Cereda, MD is currently running

Image of trial facility.

Nitric Oxide

for Acute Respiratory Distress Syndrome

Acute respiratory distress syndrome (ARDS) is when a person's lungs become inflamed, which can be caused by infection, trauma, surgery, blood transfusion, or burn. ARDS often leads to a situation where the person cannot breathe independently and needs machines' help. Once the lungs are inflamed, the small air sacs responsible for exchanging gases (i.e., ventilation) and the blood flow in the lungs (i.e., perfusion) can be affected. In the past, most research focused on studying ventilation physiology and how to help people breathe with machines. Less was done on perfusion because it requires imaging techniques such as computed tomography with intravenous contrast and radiation. One treatment option for low oxygen levels is inhaled nitric oxide (iNO), a gas that can dilate the lung blood vessels and improve oxygenation; however, it is not always clear whether this treatment will work. Electrical Impedance Tomography (EIT) is a bedside and accessible imaging technique that is radiation-free and non-invasive and can potentially detect changes in lung perfusion. EIT can perform multiple measurements; it is portable and accessible. This prospective interventional study aims to assess changes in regional blood perfusion in the lungs of patients with ARDS in response to iNO utilizing EIT. The main questions it aims to answer are: 1. If EIT can measure lung regional perfusion response to an iNO challenge of 20ppm for 15 minutes. 2. If EIT is comparable to dual-energy computed tomography (DECT), the gold-standard method to detect changes in regional lung perfusion. 3. If EIT can be an imaging marker to identify ARDS severity Participants will be divided into two cohorts: 1. Cohort 1 (n=60): Participants will be asked to be monitored by EIT before, during, and after the administration of iNO (20 ppm) for 15 minutes (OFF-ON-OFF) 2. Cohort 2 (N=10): Participants will be asked to be monitored by EIT and DECT before and during the administration of iNO (20 ppm) for 15 minutes (OFF-ON).
Recruiting1 award N/A

More about Maurizio Cereda, MD

Clinical Trial Related1 year of experience running clinical trials · Led 1 trial as a Principal Investigator · 1 Active Clinical Trial
Treatments Maurizio Cereda, MD has experience with
  • Nitric Oxide
Breakdown of trials Maurizio Cereda, MD has run
Acute Respiratory Distress Syndrome
Neonatal Respiratory Distress Syndrome

Other Doctors you might be interested in

Frequently asked questions

Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Maurizio Cereda, MD specialize in?
Maurizio Cereda, MD focuses on Acute Respiratory Distress Syndrome and Neonatal Respiratory Distress Syndrome. In particular, much of their work with Acute Respiratory Distress Syndrome has involved treating patients, or patients who are undergoing treatment.
Is Maurizio Cereda, MD currently recruiting for clinical trials?
Yes, Maurizio Cereda, MD is currently recruiting for 1 clinical trial in the USA. If you're interested in participating, you should apply.
Are there any treatments that Maurizio Cereda, MD has studied deeply?
Yes, Maurizio Cereda, MD has studied treatments such as Nitric Oxide.
What is the best way to schedule an appointment with Maurizio Cereda, MD?
Apply for one of the trials that Maurizio Cereda, MD is conducting.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.